Alexandre Reuben
A5088889988- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Cancer Genomics and Diagnostics
- CAR-T cell therapy research
- Ferroptosis and cancer prognosis
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Treatments and Mutations
- Advanced Breast Cancer Therapies
- Melanoma and MAPK Pathways
- vaccines and immunoinformatics approaches
- Cancer Research and Treatments
- Immune cells in cancer
- Immune Cell Function and Interaction
- Cancer Treatment and Pharmacology
- Cancer-related Molecular Pathways
- Microtubule and mitosis dynamics
- Neuroblastoma Research and Treatments
- RNA modifications and cancer
- Colorectal Cancer Treatments and Studies
- Radiomics and Machine Learning in Medical Imaging
- Monoclonal and Polyclonal Antibodies Research
- Polyomavirus and related diseases
- Brain Metastases and Treatment
- Lung Cancer Research Studies
- Cervical Cancer and HPV Research
The University of Texas MD Anderson Cancer Center
2016-2025
The University of Texas Health Science Center at Houston
2022-2024
Anderson University - South Carolina
2024
Texas Medical Center
2023
ORCID
2021
National Cancer Center
2020
Kyoto Prefectural University of Medicine
2018
Oregon Health & Science University
2018
Université de Montréal
2011-2017
Centre Hospitalier de l’Université de Montréal
2012-2017
Preclinical mouse models suggest that the gut microbiome modulates tumor response to checkpoint blockade immunotherapy; however, this has not been well-characterized in human cancer patients. Here we examined oral and of melanoma patients undergoing anti-programmed cell death 1 protein (PD-1) immunotherapy (
In model systems, bacteria present in human pancreatic tumors confer resistance to the anticancer drug gemcitabine.
Immune checkpoint blockade represents a major breakthrough in cancer therapy; however, responses are not universal. Genomic and immune features pretreatment tumor biopsies have been reported to correlate with response patients melanoma other cancers, but robust biomarkers identified. We studied cohort of metastatic initially treated cytotoxic T-lymphocyte-associated antigen-4 (CTLA4) (n = 53) followed by programmed death-1 (PD-1) at progression 46), analyzed signatures longitudinal tissue...
Immune checkpoint blockade produces clinical benefit in many patients. However, better biomarkers of response are still needed, and mechanisms resistance remain incompletely understood. To address this, we recently studied a cohort melanoma patients treated with sequential against cytotoxic T lymphocyte antigen-4 (CTLA-4) followed by programmed death receptor-1 (PD-1) identified immune markers resistance. Building on these studies, performed deep molecular profiling including cell receptor...
Immune checkpoint blockade therapy targets T cell-negative costimulatory molecules such as cytotoxic lymphocyte antigen-4 (CTLA-4) and programmed cell death-1 (PD-1). Combination anti–CTLA-4 anti–PD-1 has enhanced efficacy, but it remains unclear through what mechanisms effects are mediated. A critical question is whether combination modulates the same populations monotherapies. Using a mass cytometry-based systems approach, we comprehensively profiled response of to monotherapy plus in...
Abstract There is a critical need to improve our understanding of the pathogenesis melanoma brain metastases (MBM). Thus, we performed RNA sequencing on 88 resected MBMs and 42 patient-matched extracranial metastases; tumors with sufficient tissue also underwent whole-exome sequencing, T-cell receptor IHC. demonstrated heterogeneity immune infiltrates that correlated prior radiation post-craniotomy survival. Comparison identified significant immunosuppression enrichment oxidative...
Genomic intratumor heterogeneity (ITH) may be associated with postsurgical relapse of localized lung adenocarcinomas. Recently, mutations, through generation neoantigens, were shown to alter tumor immunogenicity T-cell responses. Here, we performed sequencing the receptor (TCR) in 45 regions from 11 adenocarcinomas and observed substantial differences density clonality majority clones restricted individual regions. TCR ITH positively correlated predicted neoantigen ITH, suggesting that...
Background Non-small cell lung cancer (NSCLC) patients bearing targetable oncogene alterations typically derive limited benefit from immune checkpoint blockade (ICB), which has been attributed to low tumor mutation burden (TMB) and/or PD-L1 levels. We investigated oncogene-specific differences in these markers and clinical outcome. Methods Three cohorts of NSCLC with (n=4189 total) were analyzed. Two advanced treated ICB monotherapy [MD Anderson (MDACC; n=172) Flatiron Health-Foundation...
Abstract Immunotherapy targeting T cells is increasingly utilized to treat solid tumors including non-small cell lung cancer (NSCLC). This requires a better understanding of the in lungs patients with NSCLC. Here, we report repertoire analysis cohort 236 early-stage NSCLC patients. attributes are associated clinicopathologic features, mutational and immune landscape. A considerable proportion most prevalent also uninvolved tumor-adjacent appear specific shared background mutations or viral...
Abstract Limited clinical activity has been seen in osteosarcoma (OS) patients treated with immune checkpoint inhibitors (ICI). To gain insights into the immunogenic potential of these tumors, we conducted whole genome, RNA, and T-cell receptor sequencing, immunohistochemistry reverse phase protein array profiling (RPPA) on OS specimens from 48 pediatric adult primary, relapsed, metastatic OS. Median infiltrate level was lower than other tumor types where ICI are effective, concomitant low...
Abstract Purpose: We recently reported a 17.5% objective RECIST 1.1 response rate in phase II study of pembrolizumab patients with advanced sarcoma (SARC028). The majority responses occurred undifferentiated pleomorphic (UPS) and dedifferentiated liposarcoma (DDLPS). sought to determine whether we can identify immune features that correlate clinical outcomes from tumor tissues obtained pre- on-treatment. Patients Methods: Pretreatment (n = 78) 8-week on-treatment 68) biopsies were stained...
IntroductionProgrammed death-ligand 1 (PD-L1) expression may vary in different disease sites and at time points of the course. We aimed to investigate PD-L1 heterogeneity its usefulness as a predictive value for immune checkpoint inhibitor (ICI) therapy patients with NSCLC.MethodsPD-L1 was analyzed 1398 NSCLC. The ICIs 398 metastatic NSCLC assessed.ResultsPD-L1 significantly associated biopsy (p = 0.004). Adrenal, liver, lymph node (LN) metastases had highest continuous variable 1% or 50%...
To identify disease-relevant T cell receptors (TCRs) with shared antigen specificity, we analyzed 778,938 TCRβ chain sequences from 178 non-small lung cancer patients using the GLIPH2 (grouping of lymphocyte interactions paratope hotspots 2) algorithm. We identified over 66,000 specificity groups, which 435 were clonally expanded and enriched in tumors compared to adjacent lung. The antigenic epitopes one such tumor-enriched group a yeast peptide-HLA A∗02:01 display library. These included...
Despite evidence demonstrating an overall survival benefit with up-front hormone therapy in addition to established synergy between and radiation, the of metastasis-directed (MDT) for oligometastatic prostate cancer, date, has not been evaluated a randomized clinical trial.